Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1972943

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1972943

Antimalarial Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 198 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Antimalarial Drugs Market is poised for steady growth as healthcare systems worldwide tackle the persistent threat of malaria. Valued at $1.2 billion in 2026, the market is projected to reach $2 billion by 2033, registering a CAGR of 5.20%. Increasing malaria prevalence, coupled with growing investments in research and development (R&D) and government-led initiatives, is fueling the adoption of innovative antimalarial therapies. Rising awareness, improved healthcare infrastructure, and access to effective treatments are further boosting market expansion.

Market Insights

Malaria continues to pose a significant public health challenge, particularly in tropical and subtropical regions. The demand for antimalarial drugs is intensifying due to the emergence of resistance against traditional therapies and the urgent need for highly effective treatment options. Novel drug classes, including artemisinin derivatives and combination therapies, are gaining popularity because of their superior efficacy and reduced resistance rates.

The market is also benefiting from advancements in drug formulations and delivery systems. Oral and injectable antimalarials are increasingly available, ensuring better patient compliance and treatment outcomes. Additionally, government campaigns, international funding programs, and NGO initiatives are expanding access to life-saving drugs, particularly in Africa, Asia Pacific, and Latin America.

Market Drivers

Several key factors are expected to drive the growth of the antimalarial drugs market:

  • 1. Increasing Malaria Prevalence: Millions of malaria cases continue to be reported globally each year, sustaining demand for effective medications.
  • 2. Rising Drug Resistance: Resistance to older antimalarial drugs such as chloroquine and quinine is pushing healthcare providers toward more potent alternatives, including artemisinin-based combination therapies (ACTs).
  • 3. Government and NGO Initiatives: Global programs like the Global Fund to Fight AIDS, Tuberculosis, and Malaria, along with national malaria control programs, are increasing funding for drug distribution and awareness campaigns.
  • 4. Technological Advancements: Innovations in drug formulations, including long-acting injectables and pediatric-friendly dosages, are improving treatment adherence.
  • 5. Enhanced Healthcare Awareness: Educational programs promoting early diagnosis and treatment are expanding patient reach, especially in developing regions.

Business Opportunity

The antimalarial drugs market presents significant opportunities for pharmaceutical companies, particularly in high-burden regions. Developing fixed-dose combination drugs, long-acting injectables, and pediatric formulations can capture unmet market needs. Furthermore, the rise of online pharmacies and e-commerce platforms offers new channels to distribute medications to underserved and remote populations. Companies that invest strategically in R&D, expand their geographic presence, and adopt innovative delivery methods are well-positioned to capitalize on this growing market.

Region Analysis

  • North America: Growth is driven by advanced healthcare infrastructure, research funding, and demand for malaria treatments among travelers returning from endemic areas.
  • Europe: Market expansion is supported by pharmaceutical innovations, regulatory frameworks, and increasing awareness about malaria among international travelers.
  • Asia Pacific: High malaria prevalence, government programs, and improved healthcare access in countries like India, Indonesia, and Myanmar make this a critical growth region.
  • Latin America: Steady growth is driven by regional malaria control programs, enhanced distribution networks, and awareness campaigns.
  • Middle East & Africa: Africa represents the largest market share due to the high burden of malaria, strong government programs, and international support for drug distribution.

Key Players

The antimalarial drugs market is highly competitive, with a mix of global pharmaceutical giants and regional players. Leading companies include:

  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Alvizia Healthcare Pvt. Ltd.
  • Merck & Co
  • Sanofi SA
  • GlaxoSmithKline Plc
  • Sun Pharmaceutical Industries Ltd.
  • Viatris
  • Guilin Pharmaceutical Co., Ltd.
  • Ajanta Pharma Limited
  • AbbVie Inc
  • Bayer AG
  • Cipla Limited
  • Ipca Laboratories Ltd.

These companies focus on strategic initiatives such as mergers, partnerships, product launches, and geographic expansion to strengthen their position and address the growing demand for antimalarial therapies.

Segmentation

By Drug Class:

  • Aminoquinolines
  • Quinoline-methanol (4-quinolinemethanols)
  • Cinchona Alkaloids
  • Biguanides
  • Sulfonamides and Sulfones
  • Artemisinin Derivatives
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Antimalarial Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Antimalarial Drugs Market Outlook, 2020-2033

  • 3.1. Global Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

3.1.1. AminoquinolinesBy Drug Class:

    • 3.1.2. Aminoquinolines
    • 3.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 3.1.4. Cinchona Alkaloids
    • 3.1.5. Biguanides
    • 3.1.6. Sulfonamides and Sulfones
    • 3.1.7. Artemisinin Derivatives
    • 3.1.8. Others
  • 3.2. Global Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.2.1. Oral
    • 3.2.2. Injectable
  • 3.3. Global Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospital Pharmacies
    • 3.3.2. Retail Pharmacies
    • 3.3.3. Online Pharmacies
    • 3.3.4. Other
  • 3.4. Global Antimalarial Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Antimalarial Drugs Market Outlook, 2020-2033

  • 4.1. North America Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

4.1.1. AminoquinolinesBy Drug Class:

    • 4.1.2. Aminoquinolines
    • 4.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 4.1.4. Cinchona Alkaloids
    • 4.1.5. Biguanides
    • 4.1.6. Sulfonamides and Sulfones
    • 4.1.7. Artemisinin Derivatives
    • 4.1.8. Others
  • 4.2. North America Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.2.1. Oral
    • 4.2.2. Injectable
  • 4.3. North America Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Online Pharmacies
    • 4.3.4. Other
  • 4.4. North America Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 4.4.2. U.S. Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.3. U.S. Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 4.4.5. Canada Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 4.4.6. Canada Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Antimalarial Drugs Market Outlook, 2020-2033

  • 5.1. Europe Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

5.1.1. AminoquinolinesBy Drug Class:

    • 5.1.2. Aminoquinolines
    • 5.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 5.1.4. Cinchona Alkaloids
    • 5.1.5. Biguanides
    • 5.1.6. Sulfonamides and Sulfones
    • 5.1.7. Artemisinin Derivatives
    • 5.1.8. Others
  • 5.2. Europe Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.2.1. Oral
    • 5.2.2. Injectable
  • 5.3. Europe Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
    • 5.3.4. Other
  • 5.4. Europe Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.2. Germany Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.3. Germany Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.5. Italy Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.6. Italy Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.8. France Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.9. France Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.11. U.K. Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.12. U.K. Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.14. Spain Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.15. Spain Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.17. Russia Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.18. Russia Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 5.4.20. Rest of Europe Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 5.4.21. Rest of Europe Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antimalarial Drugs Market Outlook, 2020-2033

  • 6.1. Asia Pacific Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

6.1.1. AminoquinolinesBy Drug Class:

    • 6.1.2. Aminoquinolines
    • 6.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 6.1.4. Cinchona Alkaloids
    • 6.1.5. Biguanides
    • 6.1.6. Sulfonamides and Sulfones
    • 6.1.7. Artemisinin Derivatives
    • 6.1.8. Others
  • 6.2. Asia Pacific Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.2.1. Oral
    • 6.2.2. Injectable
  • 6.3. Asia Pacific Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Other
  • 6.4. Asia Pacific Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.2. China Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.3. China Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.5. Japan Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.6. Japan Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.8. South Korea Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.9. South Korea Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.11. India Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.12. India Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.14. Southeast Asia Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.15. Southeast Asia Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 6.4.17. Rest of SAO Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 6.4.18. Rest of SAO Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antimalarial Drugs Market Outlook, 2020-2033

  • 7.1. Latin America Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

7.1.1. AminoquinolinesBy Drug Class:

    • 7.1.2. Aminoquinolines
    • 7.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 7.1.4. Cinchona Alkaloids
    • 7.1.5. Biguanides
    • 7.1.6. Sulfonamides and Sulfones
    • 7.1.7. Artemisinin Derivatives
    • 7.1.8. Others
  • 7.2. Latin America Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.2.1. Oral
    • 7.2.2. Injectable
  • 7.3. Latin America Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
    • 7.3.4. Other
  • 7.4. Latin America Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.2. Brazil Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.3. Brazil Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.5. Mexico Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.6. Mexico Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.8. Argentina Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.9. Argentina Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 7.4.11. Rest of LATAM Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 7.4.12. Rest of LATAM Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antimalarial Drugs Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033

8.1.1. AminoquinolinesBy Drug Class:

    • 8.1.2. Aminoquinolines
    • 8.1.3. Quinoline-methanol (4-quinolinemethanols)
    • 8.1.4. Cinchona Alkaloids
    • 8.1.5. Biguanides
    • 8.1.6. Sulfonamides and Sulfones
    • 8.1.7. Artemisinin Derivatives
    • 8.1.8. Others
  • 8.2. Middle East & Africa Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.2.1. Oral
    • 8.2.2. Injectable
  • 8.3. Middle East & Africa Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Other
  • 8.4. Middle East & Africa Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.2. GCC Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.3. GCC Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.5. South Africa Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.6. South Africa Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.8. Egypt Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.9. Egypt Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.11. Nigeria Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.12. Nigeria Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East Antimalarial Drugs Market Outlook, by Drug Class, 2020-2033
    • 8.4.14. Rest of Middle East Antimalarial Drugs Market Outlook, by Route of Administration, 2020-2033
    • 8.4.15. Rest of Middle East Antimalarial Drugs Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Novartis AG
    • 9.4.3. Roche Holding AG
    • 9.4.4. Alvizia Healthcare Pvt. Ltd.
    • 9.4.5. Merck & Co
    • 9.4.6. Sanofi SA
    • 9.4.7. GlaxoSmithKline Plc
    • 9.4.8. Viatris
    • 9.4.9. Guilin Pharmaceutical Co., Ltd.
    • 9.4.10. Ajanta Pharma Limited

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!